NanoEcho
0.093
SEK
-9.28 %
Less than 1K followers
NANECH
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Ownership
Investor consensus
-9.28%
-12.85%
-35.03%
-69.37%
-23.87%
-
-
-
-40.42%
NanoEcho is active in healthcare, with a main focus in rectal cancer diagnostics. The company is active in the clinical stage, where a new diagnostic method is being developed to determine whether early rectal cancer has spread to nearby lymph nodes. The method aims to provide a correct diagnosis and individualized treatment. NanoEcho was founded in 2013 and has its headquarters in Lund.
Read moreMarket cap
27.21M SEK
Turnover
87.03K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Financial calendar
21/8
2025
Interim report Q2'25
23/10
2025
Interim report Q3'25
12/2
2026
Annual report '25
All
Press releases
3rd party
ShowingAll content types
NanoEcho förlänger den finansiella uthålligheten genom riktade åtgärder
NanoEcho meddelar utfall för nyttjandet av teckningsoptioner TO1
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools